HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XFOR
X4 Pharmaceuticals, Inc.
There isn't enough reported data to score XFOR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XFOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
XFOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XFOR PE Valuation
XFOR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XFOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XFOR's revenue to grow, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus XFOR down 662%.
XFOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.12 | -$8.32 |
| Q2 2025 | -$14.83 | -549% |
| Q1 2025 | $2.14 | +$22.24 |
| Q4 2024 | -$5.70 | +$11.40 |
| Q3 2022 | -$83.10 | +$27.90 |
| Q2 2022 | -$98.10 | +$16.20 |
| Q1 2022 | -$102.30 | +$12.60 |
| Q4 2021 | -$119.70 | -$27.00 |
XFOR is still losing money, but far less than before: $10.12 per share over the past year, against $119.70 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XFOR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over XFOR on profitability, with a higher operating margin.
XFOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +79% |
| Q2 2026 | $2.4M | +38% |
| Q1 2026 | $2.5M | +178% |
| Q4 2025 | $2.2M | +53% |
| Q3 2025 | $1.6M | +180% |
| Q2 2025 | $1.7M | +210% |
XFOR's revenue has grown year over year for 10 quarters in a row: $3M last quarter, up 79% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -714% | +1043 points |
| Q2 2026 | -683% | +821 points |
| Q1 2026 | -812% | +237 points |
| Q4 2025 | -1077% | +1413 points |
| Q3 2025 | -1757% | +4404 points |
| Q2 2025 | -1504% | -14133 points |
| Q1 2025 | -1049% | N/A |
| Q4 2024 | -2491% | N/A |
XFOR's operating margin was −714% last quarter, up 1043 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XFOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XFOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | +$7.6M |
| Q2 2026 | -$20.8M | +$9.1M |
| Q1 2026 | -$19.6M | -$7.2M |
| Q4 2025 | -$15.5M | +$17.5M |
| Q3 2025 | -$27.8M | +$6.3M |
| Q2 2025 | -$29.9M | +$34.1M |
| Q1 2025 | -$12.4M | +$21.3M |
| Q4 2024 | -$33M | -$5.3M |
XFOR has burned cash in almost every quarter: −$76M over the past year, against −$103M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XFOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XFOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +180K shares |
| 1 year | +1607% | +119M shares |
| 3 years | +2149% | +121M shares |
| 5 years | +18192% | +126M shares |
| Available history | +18865% | +126M shares |
XFOR has 127M diluted shares, up 1607% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | $443,000 |
| Q4 2022 | — |
| Q4 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XFOR Net Leverage
XFOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XFOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 34.5 | Neutral |
XFOR's weekly RSI is 44 (neutral) and its Stochastic is 35 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XFOR PE vs Healthcare Sector
| Metric | XFOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XFOR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XFOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 4.3% above |
| 20 week MA | $3.63 | 13% below |
| 50 week MA | $3.81 | 17% below |
| 100 week MA | $5.35 | 41% below |
| 200 week MA | $18.2 | 83% below |
XFOR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XFOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $325.8 | $210.3 | -35% |
| 2021 | $210.3 | $74.1 | -65% |
| 2022 | $74.1 | $25.8 | -65% |
| 2023 | $25.8 | $25.2 | -2.6% |
| 2024 | $25.2 | $24.1 | -4.1% |
| 2025 | $24.1 | $4.50 | -81% |
| 2026 YTD | $4.50 | $3.17 | -30% |
XFOR has the edge over HIMS on returns for 2026, with the stronger performance.